U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Fatty liver disease, nonalcoholic, susceptibility to, 2(FLD2)

MedGen UID:
462001
Concept ID:
C3150651
Finding
Synonyms: Fatty liver disease, nonalcoholic 2; FLD2; NAFLD2
 
Monarch Initiative: MONDO:0013246
OMIM®: 613387

Definition

NAFLD and NASH are thought to account for many cases of cirrhosis that have no obvious underlying cause (cryptogenic cirrhosis); at least one-third of people with NASH eventually develop cirrhosis. People with NAFLD, NASH, and cirrhosis are also at increased risk of developing liver cancer (hepatocellular cancer).

NAFLD is most common in middle-aged or older people, although younger people, including children, are also affected. It is often considered as part of a group of conditions known collectively as the metabolic syndrome; in addition to NAFLD, the metabolic syndrome includes obesity, type 2 diabetes or pre-diabetes (insulin resistance), high levels of fats (lipids) such as cholesterol and triglycerides in the blood, and high blood pressure (hypertension). However, a person with NAFLD may not have all or any of the other conditions that make up the metabolic syndrome, and individuals with some or all of those conditions may not have NAFLD.

Between 7 and 30 percent of people with NAFLD develop inflammation of the liver (non-alcoholic steatohepatitis, also known as NASH), leading to liver damage. Minor damage to the liver can be repaired by the body. However, severe or long-term damage can lead to the replacement of normal liver tissue with scar tissue (fibrosis), resulting in irreversible liver disease (cirrhosis) that causes the liver to stop working properly. Signs and symptoms of cirrhosis, which get worse as fibrosis affects more of the liver, include fatigue, weakness, loss of appetite, weight loss, nausea, swelling (edema), and yellowing of the skin and whites of the eyes (jaundice). Scarring in the vein that carries blood into the liver from the other digestive organs (the portal vein) can lead to increased pressure in that blood vessel (portal hypertension), resulting in swollen blood vessels (varices) within the digestive system. Rupture of these varices can cause life-threatening bleeding.

The fat deposits in the liver associated with NAFLD usually cause no symptoms, although they may cause increased levels of liver enzymes that are detected in routine blood tests. Some affected individuals have abdominal pain or fatigue. During a physical examination, the liver may be found to be slightly enlarged.

Non-alcoholic fatty liver disease (NAFLD) is a buildup of excessive fat in the liver that can lead to liver damage resembling the damage caused by alcohol abuse, but that occurs in people who do not drink heavily. The liver is a part of the digestive system that helps break down food, store energy, and remove waste products, including toxins. The liver normally contains some fat; an individual is considered to have a fatty liver (hepatic steatosis) if the liver contains more than 5 to 10 percent fat. [from MedlinePlus Genetics]

Clinical features

From HPO
Hepatic steatosis
MedGen UID:
398225
Concept ID:
C2711227
Disease or Syndrome
Steatosis is a term used to denote lipid accumulation within hepatocytes.

Professional guidelines

PubMed

Pafili K, Roden M
Mol Metab 2021 Aug;50:101122. Epub 2020 Nov 19 doi: 10.1016/j.molmet.2020.101122. PMID: 33220492Free PMC Article
Milosevic I, Vujovic A, Barac A, Djelic M, Korac M, Radovanovic Spurnic A, Gmizic I, Stevanovic O, Djordjevic V, Lekic N, Russo E, Amedei A
Int J Mol Sci 2019 Jan 17;20(2) doi: 10.3390/ijms20020395. PMID: 30658519Free PMC Article
Kumar S, Kelly AS
Mayo Clin Proc 2017 Feb;92(2):251-265. Epub 2017 Jan 5 doi: 10.1016/j.mayocp.2016.09.017. PMID: 28065514

Recent clinical studies

Etiology

He F, Zhang P, Liu J, Wang R, Kaufman RJ, Yaden BC, Karin M
J Hepatol 2023 Aug;79(2):362-377. Epub 2023 Mar 28 doi: 10.1016/j.jhep.2023.03.016. PMID: 36996941
Hou J, Zhang J, Cui P, Zhou Y, Liu C, Wu X, Ji Y, Wang S, Cheng B, Ye H, Shu L, Zhang K, Wang D, Xu J, Shu Q, Colonna M, Fang X
J Clin Invest 2021 Feb 15;131(4) doi: 10.1172/JCI135197. PMID: 33586673Free PMC Article
Pafili K, Roden M
Mol Metab 2021 Aug;50:101122. Epub 2020 Nov 19 doi: 10.1016/j.molmet.2020.101122. PMID: 33220492Free PMC Article
Meroni M, Longo M, Rustichelli A, Dongiovanni P
Int J Mol Sci 2020 Apr 23;21(8) doi: 10.3390/ijms21082986. PMID: 32340286Free PMC Article
Labib PL, Goodchild G, Pereira SP
BMC Cancer 2019 Feb 28;19(1):185. doi: 10.1186/s12885-019-5391-0. PMID: 30819129Free PMC Article

Diagnosis

Tilg H, Adolph TE, Dudek M, Knolle P
Nat Metab 2021 Dec;3(12):1596-1607. Epub 2021 Dec 20 doi: 10.1038/s42255-021-00501-9. PMID: 34931080
Pushpanathan P, Mathew GS, Selvarajan S, Seshadri KG, Srikanth P
Indian J Med Microbiol 2019 Apr-Jun;37(2):268-277. doi: 10.4103/ijmm.IJMM_19_373. PMID: 31745030
Labib PL, Goodchild G, Pereira SP
BMC Cancer 2019 Feb 28;19(1):185. doi: 10.1186/s12885-019-5391-0. PMID: 30819129Free PMC Article
Stefan N, Häring HU, Cusi K
Lancet Diabetes Endocrinol 2019 Apr;7(4):313-324. Epub 2018 Aug 30 doi: 10.1016/S2213-8587(18)30154-2. PMID: 30174213
Eslam M, Valenti L, Romeo S
J Hepatol 2018 Feb;68(2):268-279. Epub 2017 Nov 6 doi: 10.1016/j.jhep.2017.09.003. PMID: 29122391

Therapy

Dudek M, Pfister D, Donakonda S, Filpe P, Schneider A, Laschinger M, Hartmann D, Hüser N, Meiser P, Bayerl F, Inverso D, Wigger J, Sebode M, Öllinger R, Rad R, Hegenbarth S, Anton M, Guillot A, Bowman A, Heide D, Müller F, Ramadori P, Leone V, Garcia-Caceres C, Gruber T, Seifert G, Kabat AM, Mallm JP, Reider S, Effenberger M, Roth S, Billeter AT, Müller-Stich B, Pearce EJ, Koch-Nolte F, Käser R, Tilg H, Thimme R, Boettler T, Tacke F, Dufour JF, Haller D, Murray PJ, Heeren R, Zehn D, Böttcher JP, Heikenwälder M, Knolle PA
Nature 2021 Apr;592(7854):444-449. Epub 2021 Mar 24 doi: 10.1038/s41586-021-03233-8. PMID: 33762736
Safari Z, Gérard P
Cell Mol Life Sci 2019 Apr;76(8):1541-1558. Epub 2019 Jan 25 doi: 10.1007/s00018-019-03011-w. PMID: 30683985
Stefan N, Häring HU, Cusi K
Lancet Diabetes Endocrinol 2019 Apr;7(4):313-324. Epub 2018 Aug 30 doi: 10.1016/S2213-8587(18)30154-2. PMID: 30174213
Kumar S, Kelly AS
Mayo Clin Proc 2017 Feb;92(2):251-265. Epub 2017 Jan 5 doi: 10.1016/j.mayocp.2016.09.017. PMID: 28065514
Paradies G, Paradies V, Ruggiero FM, Petrosillo G
World J Gastroenterol 2014 Oct 21;20(39):14205-18. doi: 10.3748/wjg.v20.i39.14205. PMID: 25339807Free PMC Article

Prognosis

Anstee QM, Darlay R, Cockell S, Meroni M, Govaere O, Tiniakos D, Burt AD, Bedossa P, Palmer J, Liu YL, Aithal GP, Allison M, Yki-Järvinen H, Vacca M, Dufour JF, Invernizzi P, Prati D, Ekstedt M, Kechagias S, Francque S, Petta S, Bugianesi E, Clement K, Ratziu V, Schattenberg JM, Valenti L, Day CP, Cordell HJ, Daly AK; EPoS Consortium Investigators
J Hepatol 2020 Sep;73(3):505-515. Epub 2020 Apr 13 doi: 10.1016/j.jhep.2020.04.003. PMID: 32298765
Pushpanathan P, Mathew GS, Selvarajan S, Seshadri KG, Srikanth P
Indian J Med Microbiol 2019 Apr-Jun;37(2):268-277. doi: 10.4103/ijmm.IJMM_19_373. PMID: 31745030
Stefan N, Häring HU, Cusi K
Lancet Diabetes Endocrinol 2019 Apr;7(4):313-324. Epub 2018 Aug 30 doi: 10.1016/S2213-8587(18)30154-2. PMID: 30174213
Eslam M, Valenti L, Romeo S
J Hepatol 2018 Feb;68(2):268-279. Epub 2017 Nov 6 doi: 10.1016/j.jhep.2017.09.003. PMID: 29122391
Fan JG, Kim SU, Wong VW
J Hepatol 2017 Oct;67(4):862-873. Epub 2017 Jun 19 doi: 10.1016/j.jhep.2017.06.003. PMID: 28642059

Clinical prediction guides

Anstee QM, Darlay R, Cockell S, Meroni M, Govaere O, Tiniakos D, Burt AD, Bedossa P, Palmer J, Liu YL, Aithal GP, Allison M, Yki-Järvinen H, Vacca M, Dufour JF, Invernizzi P, Prati D, Ekstedt M, Kechagias S, Francque S, Petta S, Bugianesi E, Clement K, Ratziu V, Schattenberg JM, Valenti L, Day CP, Cordell HJ, Daly AK; EPoS Consortium Investigators
J Hepatol 2020 Sep;73(3):505-515. Epub 2020 Apr 13 doi: 10.1016/j.jhep.2020.04.003. PMID: 32298765
Labib PL, Goodchild G, Pereira SP
BMC Cancer 2019 Feb 28;19(1):185. doi: 10.1186/s12885-019-5391-0. PMID: 30819129Free PMC Article
Safari Z, Gérard P
Cell Mol Life Sci 2019 Apr;76(8):1541-1558. Epub 2019 Jan 25 doi: 10.1007/s00018-019-03011-w. PMID: 30683985
Stefan N, Häring HU, Cusi K
Lancet Diabetes Endocrinol 2019 Apr;7(4):313-324. Epub 2018 Aug 30 doi: 10.1016/S2213-8587(18)30154-2. PMID: 30174213
Sookoian S, Pirola CJ
World J Gastroenterol 2015 Jan 21;21(3):711-25. doi: 10.3748/wjg.v21.i3.711. PMID: 25624707Free PMC Article

Recent systematic reviews

Boeckmans J, Gatzios A, Schattenberg JM, Koek GH, Rodrigues RM, Vanhaecke T
Liver Int 2023 May;43(5):975-988. Epub 2023 Feb 16 doi: 10.1111/liv.15533. PMID: 36719059
Zhu Y, Yang JH, Hu JP, Qiao M
Medicine (Baltimore) 2022 Sep 23;101(38):e30803. doi: 10.1097/MD.0000000000030803. PMID: 36197156Free PMC Article
Salari N, Darvishi N, Mansouri K, Ghasemi H, Hosseinian-Far M, Darvishi F, Mohammadi M
BMC Endocr Disord 2021 Jun 19;21(1):125. doi: 10.1186/s12902-021-00789-4. PMID: 34147109Free PMC Article
Singh A, Hussain S, Antony B
Diabetes Metab Syndr 2021 May-Jun;15(3):813-822. Epub 2021 Mar 31 doi: 10.1016/j.dsx.2021.03.019. PMID: 33862417Free PMC Article
Sookoian S, Pirola CJ
Hepatology 2011 Jun;53(6):1883-94. Epub 2011 May 14 doi: 10.1002/hep.24283. PMID: 21381068

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...